Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Amgen Reports Second Quarter 2018 Financial Results

      Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)

      News provided by

      Amgen

      Jul 26, 2018, 16:01 ET

      Share this article

      Share this article


      THOUSAND OAKS, Calif., July 26, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2018. Key results include:

      • Total revenues increased 4 percent versus the second quarter of 2017 to $6.1 billion.
        • Product sales grew 2 percent globally. New and recently launched products including Repatha® (evolocumab), KYPROLIS® (carfilzomib), Prolia® (denosumab) and XGEVA® (denosumab), showed double-digit growth.
      • GAAP earnings per share (EPS) increased 20 percent to $3.48 driven by higher product sales, a lower tax rate and lower weighted-average shares outstanding.
        • GAAP operating income increased 5 percent to $2.8 billion and GAAP operating margin increased 1.5 percentage points to 49.9 percent.
      • Non-GAAP EPS increased 17 percent to $3.83 driven by higher product sales, a lower tax rate and lower weighted-average shares outstanding.
        • Non-GAAP operating income increased 2 percent to $3.1 billion and non-GAAP operating margin decreased 0.1 percentage points to 55.1 percent.
      • 2018 EPS guidance revised to $11.83-$12.62 on a GAAP basis and $13.30-$14.00 on a non-GAAP basis; total revenues guidance revised to $22.5-$23.2 billion.
      • The Company generated $1.9 billion of free cash flow in the second quarter versus $2.1 billion in the second quarter of 2017.

      "Amgen's strong performance in the second quarter was driven by double-digit, volume-driven growth from our new and recently launched products," said Robert A. Bradway, chairman and chief executive officer. "Our two most recently launched products, Aimovig and Parsabiv, are off to a strong start."

      $Millions, except EPS and percentages

      Q2'18


      Q2'17


      YOY Δ







      Total Revenues

      $ 6,059


      $ 5,810


      4%

      GAAP Operating Income

      $ 2,832


      $ 2,698


      5%

      GAAP Net Income

      $ 2,296


      $ 2,151


      7%

      GAAP Earnings Per Share

      $   3.48


      $   2.91


      20%

      Non-GAAP Operating Income

      $ 3,131


      $ 3,075


      2%

      Non-GAAP Net Income

      $ 2,529


      $ 2,410


      5%

      Non-GAAP EPS

      $   3.83


      $   3.27


      17%








      References in this release to "non-GAAP" measures, measures presented "on a non-GAAP basis" and to "free cash flow" (computed by subtracting capital expenditures from operating cash flow) refer to non-GAAP financial measures. Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations.

      Product Sales Performance

      • Total product sales increased 2 percent for the second quarter of 2018 versus the second quarter of 2017.
      • Repatha sales increased 78 percent driven primarily by higher unit demand, offset partially by net selling price.
      • BLINCYTO® (blinatumomab) sales increased 40 percent driven by higher unit demand.
      • KYPROLIS sales increased 25 percent driven by higher unit demand, offset partially by net selling price.
      • Prolia sales increased 21 percent driven primarily by higher unit demand and, to a lesser extent, net selling price.
      • XGEVA sales increased 14 percent driven primarily by higher unit demand and, to a lesser extent, net selling price.
      • Nplate® (romiplostim) sales increased 9 percent driven by higher unit demand, offset partially by net selling price.
      • Vectibix® (panitumumab) sales increased 3 percent driven primarily by higher unit demand, offset partially by net selling price.
      • Neulasta® (pegfilgrastim) sales increased 1 percent driven by an increase in net selling price and, to a lesser extent, favorable changes in inventory, offset partially by lower unit demand.
      • Sensipar/Mimpara® (cinacalcet) sales decreased 2 percent driven by unfavorable changes in inventory and lower unit demand as a function of Parsabiv uptake, offset partially by higher net selling price.
      • Parsabiv™ (etelcalcetide) was launched in the U.S. in the first quarter of 2018.
      • Enbrel® (etanercept) sales decreased 11 percent driven primarily by unfavorable changes in inventory and lower unit demand.
      • Aranesp® (darbepoetin alfa) sales decreased 12 percent driven primarily by the impact of competition on unit demand and, to a lesser extent, net selling price.
      • EPOGEN® (epoetin alfa) sales decreased 14 percent driven primarily by lower net selling price and, to a lesser extent, lower unit demand.
      • NEUPOGEN® (filgrastim) sales decreased 26 percent driven primarily by the impact of competition on unit demand and, to a lesser extent, net selling price.

      Product Sales Detail by Product and Geographic Region

      $Millions, except percentages


      Q2'18


      Q2'17


      YOY Δ



      US

      ROW

      TOTAL


      TOTAL


      TOTAL










      Repatha®

      $98

      $50

      $148


      $83


      78%

      BLINCYTO®

      34

      26

      60


      43


      40%

      KYPROLIS®


      151

      112

      263


      211


      25%

      Prolia®


      396

      214

      610


      505


      21%

      XGEVA®


      339

      113

      452


      395


      14%

      Nplate®


      107

      72

      179


      164


      9%

      Vectibix®


      68

      105

      173


      168


      3%

      Neulasta®


      948

      152

      1,100


      1,087


      1%

      Sensipar® / Mimpara®


      330

      90

      420


      427


      (2%)

      Parsabiv™


      66

      7

      73


      -


      *

      Enbrel®


      1,252

      50

      1,302


      1,466


      (11%)

      Aranesp®


      241

      231

      472


      535


      (12%)

      EPOGEN®


      250

      -

      250


      292


      (14%)

      NEUPOGEN®


      63

      39

      102


      137


      (26%)

      Other**


      24

      51

      75


      61


      23%










      Total product sales


      $4,367

      $1,312

      $5,679


      $5,574


      2%










      * Change in excess of 100%





      ** Other includes Bergamo, MN Pharma, IMLYGIC®, Corlanor®, AimovigTM and KANJINTITM











      KANJINTITM trade name is provisionally approved by the FDA



      Operating Expense, Operating Margin and Tax Rate Analysis

      On a GAAP basis:

      • Total Operating Expenses increased 4 percent due to investments in newer and recently launched products, and all expense categories also reflect savings from our transformation and process improvement efforts. Cost of Sales margin decreased by 0.4 points due to favorable royalty cost and lower acquisition-related intangible amortization, partially offset by higher manufacturing cost and unfavorable product mix. Research & Development (R&D) expenses were flat. Selling, General & Administrative (SG&A) expenses increased 12 percent due to investments in product launches and marketed product support.
      • Operating Margin improved by 1.5 percentage points to 49.9 percent.
      • Tax Rate decreased by 2.1 percentage points due to the impacts of U.S. corporate tax reform, offset partially by a prior year benefit associated with the effective settlement of certain state and federal tax matters.

      On a non-GAAP basis:

      • Total Operating Expenses increased 7 percent due to investments in newer and recently launched products, and all expense categories also reflect savings from our transformation and process improvement efforts. Cost of Sales margin increased by 0.4 points driven by higher manufacturing cost and unfavorable product mix, partially offset by lower royalty expense. R&D expenses were flat. SG&A expenses increased 14 percent due to investments in product launches and marketed product support.
      • Operating Margin decreased by 0.1 percentage points to 55.1 percent.
      • Tax Rate decreased by 3.2 percentage points due to the impacts of U.S. corporate tax reform, offset partially by a prior year benefit associated with the effective settlement of certain state and federal tax matters.

      $Millions, except percentages

















      GAAP


      Non-GAAP





      Q2'18


      Q2'17


      YOY Δ


      Q2'18


      Q2'17


      YOY Δ
















      Cost of Sales

      $1,024


      $1,024


      0%


      $745


      $710


      5%



      % of product sales

      18.0%


      18.4%


      (0.4) pts


      13.1%


      12.7%


      0.4 pts

      Research & Development

      $869


      $873


      0%


      $850


      $851


      0%



      % of product sales

      15.3%


      15.7%


      (0.4) pts


      15.0%


      15.3%


      (0.3) pts

      Selling, General & Administrative

      $1,353


      $1,209


      12%


      $1,333


      $1,174


      14%



      % of product sales

      23.8%


      21.7%


      2.1 pts


      23.5%


      21.1%


      2.4 pts

      Other

      ($19)


      $6


      *


      $0


      $0


      NM

      TOTAL Operating Expenses

      $3,227


      $3,112


      4%


      $2,928


      $2,735


      7%
















      Operating Margin














      operating income as a % of product sales

      49.9%


      48.4%


      1.5 pts


      55.1%


      55.2%


      (0.1) pts
















      Tax Rate

      13.3%


      15.4%


      (2.1) pts


      14.2%


      17.4%


      (3.2) pts
















      * Change in excess of 100%








      NM: Not Meaningful








      pts: percentage points








      Cash Flow and Balance Sheet        

      • The Company generated $1.9 billion of free cash flow in the second quarter of 2018 versus $2.1 billion in the second quarter of 2017 driven by higher cash taxes resulting from the first installment of the repatriation tax paid in the second quarter of 2018, partially offset by a lower ongoing income tax liability as well as higher net income.
      • The Company's second quarter 2018 dividend of $1.32 per share was paid on June 8, 2018, a 15 percent increase versus the second quarter of 2017.
      • During the second quarter, the Company repurchased 18.2 million shares of common stock at a total cost of $3.2 billion. At the end of the second quarter, the Company had $5.4 billion remaining under its stock repurchase authorization.

      $Billions, except shares


      Q2'18


      Q2'17


      YOY Δ










      Operating Cash Flow

      $2.1


      $2.3


      ($0.2)

      Capital Expenditures

      0.2


      0.2


      0.0

      Free Cash Flow

      1.9


      2.1


      (0.2)

      Dividends Paid

      0.9


      0.8


      0.0

      Share Repurchase

      3.2


      1.0


      2.2

      Avg. Diluted Shares (millions)

      660


      738


      (78)










      Cash and Investments

      29.4


      39.2


      (9.8)

      Debt Outstanding

      34.5


      35.1


      (0.6)

      Stockholders' Equity

      14.9


      31.7


      (16.8)












      Note: Numbers may not add due to rounding







      2018 Guidance

      For the full year 2018, the Company now expects:

      • Total revenues in the range of $22.5 billion to $23.2 billion.
        • Previously, the Company expected total revenues in the range of $21.9 billion to $22.8 billion.
      • On a GAAP basis, EPS in the range of $11.83 to $12.62 and a tax rate in the range of 12.5 percent to 13.5 percent.
        • Previously, the Company expected GAAP EPS in the range of $11.30 to $12.28.  Tax rate guidance is unchanged.
      • On a non-GAAP basis, EPS in the range of $13.30 to $14.00 and a tax rate in the range of 13.5 percent to 14.5 percent.
        • Previously, the Company expected non-GAAP EPS in the range of $12.80 to $13.70.  Tax rate guidance is unchanged.
      • Capital expenditures to be approximately $750 million.

      Second Quarter Product and Pipeline Update
      The Company provided the following updates on selected product and pipeline programs:

      AimovigTM (erenumab-aooe)

      • In May, the U.S. Food and Drug Administration (FDA) approved Aimovig for the preventive treatment of migraine in adults.
      • In June, the Company submitted a supplemental Biologics License Application (BLA) to the FDA for the 140 mg Sureclick® autoinjector device and 140 mg prefilled syringe.

      KYPROLIS

      • In April, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending a label variation for KYPROLIS to include the overall survival (OS) data from the Phase 3 ASPIRE trial.
      • In June, the FDA approved the supplemental New Drug Application to add the OS data from the Phase 3 ASPIRE trial to the U.S. Prescribing Information.

      BLINCYTO

      • In June, the European Commission (EC) granted a full marketing authorization for BLINCYTO based on the OS data from the Phase 3 TOWER study in adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

      Repatha 

      • In May, the EC approved a new indication for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering lipoprotein cholesterol (LDL-C) levels.

      Prolia

      • In May and June, the FDA and EC, respectively, approved a new indication for the treatment of glucocorticoid-induced osteoporosis in adults.

      EVENITYTM (romosozumab)

      • In July, Amgen and UCB announced the resubmission of the BLA to the FDA for the treatment of osteoporosis in postmenopausal women at high risk for fracture.

      KANJINTITM (ABP 980)

      • In May, the EC granted marketing authorization for KANJINTI, a biosimilar to Herceptin® (trastuzumab), for the treatment of HER2-positive metastatic breast cancer, HER2-positive early breast cancer and HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction.
      • In May, the Company received a complete response letter from the FDA on its BLA.

      ABP 710 (biosimilar infliximab)

      • In June, the Company announced results from the primary analysis of a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 710 compared with REMICADE® (infliximab) in patients with moderate-to-severe rheumatoid arthritis. The results confirm noninferiority compared to infliximab but could not rule out superiority based on the primary efficacy endpoint.

      Amgen Announces Succession Plans for Two Executive Officers
      As part of Amgen's planned executive succession to address upcoming retirements, the Company announced that Sean E. Harper, M.D., executive vice president of Research and Development, will be retiring from his current role at Amgen and will be succeeded by David M. Reese, M.D., currently senior vice president of Translational Sciences and Oncology at Amgen. The Company also announced that Anthony C. Hooper, executive vice president of Global Commercial Operations, will be retiring from his current role in September and will be succeeded by Murdo Gordon, chief commercial officer of Bristol-Myers Squibb Company. Details of these plans are the subject of a separate Amgen press release.

      EVENITY and KANJINTI trade names provisionally approved by FDA
      EVENITY is developed in collaboration with UCB globally, as well as our joint venture partner Astellas in Japan
      Aimovig is developed in collaboration with Novartis
      Herceptin is a registered trademark of Genentech
      Remicade is a registered trademark of Johnson and Johnson

      Non-GAAP Financial Measures
      In this news release, management has presented its operating results for the second quarters of 2018 and 2017, in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and on a non-GAAP basis. In addition, management has presented its full year 2018 EPS and tax rate guidance in accordance with GAAP and on a non-GAAP basis. These non-GAAP financial measures are computed by excluding certain items related to acquisitions, restructuring and certain other items from the related GAAP financial measures. Reconciliations for these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the news release. Management has also presented Free Cash Flow (FCF), which is a non-GAAP financial measure, for the second quarters of 2018 and 2017. FCF is computed by subtracting capital expenditures from operating cash flow, each as determined in accordance with GAAP.

      The Company believes that its presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses certain non-GAAP financial measures to enhance an investor's overall understanding of the financial performance and prospects for the future of the Company's ongoing business activities by facilitating comparisons of results of ongoing business operations among current, past and future periods. The Company believes that FCF provides a further measure of the Company's liquidity.

      The Company uses the non-GAAP financial measures set forth in the news release in connection with its own budgeting and financial planning internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. The non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

      About Amgen
      Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

      Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. 

      For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

      Forward-Looking Statements
      This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

      No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

      CONTACT:  Amgen, Thousand Oaks
      Trish Hawkins, 805-447-5631 (media)
      Arvind Sood, 805-447-1060 (investors)

      Amgen Inc.

      Consolidated Statements of Income - GAAP

      (In millions, except per share data)

      (Unaudited)














      Three months ended


      Six months ended




      June 30,


      June 30,




      2018


      2017


      2018


      2017

      Revenues:









      Product sales

      $ 5,679


      $ 5,574


      $ 11,022


      $ 10,773


      Other revenues

      380


      236


      591


      501



      Total revenues

      6,059


      5,810


      11,613


      11,274











      Operating expenses:









      Cost of sales

      1,024


      1,024


      1,968


      2,020


      Research and development

      869


      873


      1,629


      1,642


      Selling, general and administrative

      1,353


      1,209


      2,480


      2,273


      Other

      (19)


      6


      (22)


      50



      Total operating expenses

      3,227


      3,112


      6,055


      5,985











      Operating income

      2,832


      2,698


      5,558


      5,289











      Interest expense, net

      347


      321


      685


      647

      Interest and other income, net

      162


      165


      393


      360











      Income before income taxes

      2,647


      2,542


      5,266


      5,002











      Provision for income taxes

      351


      391


      659


      780











      Net income

      $ 2,296


      $ 2,151


      $   4,607


      $   4,222











      Earnings per share:









      Basic

      $   3.50


      $   2.93


      $     6.76


      $     5.74


      Diluted

      $   3.48


      $   2.91


      $     6.73


      $     5.71











      Weighted-average shares used in calculation of earnings per share:









      Basic

      656


      734


      682


      736


      Diluted

      660


      738


      685


      740

      Amgen Inc.

      Consolidated Balance Sheets - GAAP

      (In millions)












      June 30, 


      December 31,





      2018


      2017








      Assets




      Current assets:




      Cash, cash equivalents and marketable securities

      $          29,395


      $           41,678


      Trade receivables, net

      3,504


      3,237


      Inventories

      3,063


      2,834


      Other current assets

      2,008


      1,727




      Total current assets

      37,970


      49,476

      Property, plant and equipment, net

      4,922


      4,989

      Intangible assets, net

      8,443


      8,609

      Goodwill

      14,724


      14,761

      Other assets

      1,625


      2,119

      Total assets

      $         67,684


      $           79,954








      Liabilities and Stockholders' Equity




      Current liabilities:





      Accounts payable and accrued liabilities

      $           6,917


      $             7,868


      Current portion of long-term debt

      4,288


      1,152




      Total current liabilities

      11,205


      9,020

      Long-term debt

      30,209


      34,190

      Long-term deferred tax liabilities

      1,155


      1,166

      Long-term tax liabilities


      8,763


      9,099

      Other noncurrent liabilities

      1,443


      1,238

      Stockholders' equity

      14,909


      25,241

      Total liabilities and stockholders' equity

      $         67,684


      $           79,954








      Shares outstanding

      649


      722


      Amgen Inc.

      GAAP to Non-GAAP Reconciliations

      (Dollars in millions)

      (Unaudited)












      Three months ended


      Six months ended



      June 30, 


      June 30,



      2018


      2017


      2018


      2017











      GAAP cost of sales

      $ 1,024


      $     1,024


      $ 1,968


      $     2,020


      Adjustments to cost of sales:









      Acquisition-related expenses (a)

      (279)


      (314)


      (545)


      (628)


      Total adjustments to cost of sales

      (279)


      (314)


      (545)


      (628)


      Non-GAAP cost of sales

      $    745


      $        710


      $ 1,423


      $     1,392











      GAAP cost of sales as a percentage of product sales

      18.0%


      18.4%


      17.9%


      18.8%


      Acquisition-related expenses (a)

      -4.9


      -5.7


      -5.0


      -5.9


      Non-GAAP cost of sales as a percentage of product sales

      13.1%


      12.7%


      12.9%


      12.9%











      GAAP research and development expenses

      $    869


      $        873


      $ 1,629


      $     1,642


      Adjustments to research and development expenses:









      Acquisition-related expenses (a)

      (19)


      (19)


      (40)


      (38)


      Certain net charges pursuant to our restructuring initiative

      -


      (3)


      -


      (5)


      Total adjustments to research and development expenses

      (19)


      (22)


      (40)


      (43)


      Non-GAAP research and development expenses

      $    850


      $        851


      $ 1,589


      $     1,599











      GAAP research and development expenses as a percentage of product sales

      15.3%


      15.7%


      14.8%


      15.2%


      Acquisition-related expenses (a)

      -0.3


      -0.3


      -0.4


      -0.3


      Certain net charges pursuant to our restructuring initiative

      0.0


      -0.1


      0.0


      -0.1


      Non-GAAP research and development expenses as a percentage of product sales

      15.0%


      15.3%


      14.4%


      14.8%











      GAAP selling, general and administrative expenses

      $ 1,353


      $     1,209


      $ 2,480


      $     2,273


      Adjustments to selling, general and administrative expenses:









      Acquisition-related expenses (a)

      (20)


      (32)


      (45)


      (57)


      Certain net charges pursuant to our restructuring initiative

      -


      -


      (3)


      -


      Other

      -


      (3)


      -


      (3)


      Total adjustments to selling, general and administrative expenses

      (20)


      (35)


      (48)


      (60)


      Non-GAAP selling, general and administrative expenses

      $ 1,333


      $     1,174


      $ 2,432


      $     2,213











      GAAP selling, general and administrative expenses as a percentage of product sales

      23.8%


      21.7%


      22.5%


      21.1%


      Acquisition-related expenses (a)

      -0.3


      -0.5


      -0.4


      -0.6


      Certain net charges pursuant to our restructuring initiative

      0.0


      0.0


      0.0


      0.0


      Other

      0.0


      -0.1


      0.0


      0.0


      Non-GAAP selling, general and administrative expenses as a percentage of product sales

      23.5%


      21.1%


      22.1%


      20.5%











      GAAP operating expenses

      $ 3,227


      $     3,112


      $ 6,055


      $     5,985


      Adjustments to operating expenses:









      Adjustments to cost of sales

      (279)


      (314)


      (545)


      (628)


      Adjustments to research and development expenses

      (19)


      (22)


      (40)


      (43)


      Adjustments to selling, general and administrative expenses

      (20)


      (35)


      (48)


      (60)


      Certain net charges pursuant to our restructuring initiative (b)

      7


      (9)


      6


      (46)


      Certain other expenses

      (25)


      -


      (25)


      -


      Acquisition-related adjustments (c)

      37


      3


      41


      (4)


      Total adjustments to operating expenses

      (299)


      (377)


      (611)


      (781)


      Non-GAAP operating expenses

      $ 2,928


      $     2,735


      $ 5,444


      $     5,204











      GAAP operating income

      $ 2,832


      $     2,698


      $ 5,558


      $     5,289


      Adjustments to operating expenses

      299


      377


      611


      781


      Non-GAAP operating income

      $ 3,131


      $     3,075


      $ 6,169


      $     6,070











      GAAP operating income as a percentage of product sales

      49.9%


      48.4%


      50.4%


      49.1%


      Adjustments to cost of sales

      4.9


      5.7


      5.0


      5.9


      Adjustments to research and development expenses

      0.3


      0.4


      0.4


      0.4


      Adjustments to selling, general and administrative expenses

      0.3


      0.6


      0.4


      0.6


      Certain net charges pursuant to our restructuring initiative (b)

      0.0


      0.2


      0.0


      0.3


      Certain other expenses

      0.4


      0.0


      0.2


      0.0


      Acquisition-related adjustments (c)

      -0.7


      -0.1


      -0.4


      0.0


      Non-GAAP operating income as a percentage of product sales

      55.1%


      55.2%


      56.0%


      56.3%











      GAAP interest and other income, net

      $    162


      $        165


      $    393


      $        360


      Adjustments to other income (d) 

      -


      -


      (75)


      -


      Non-GAAP interest and other income, net

      $    162


      $        165


      $    318


      $        360











      GAAP income before income taxes

      $ 2,647


      $     2,542


      $ 5,266


      $     5,002


      Adjustments to operating expenses

      299


      377


      611


      781


      Adjustments to other income (d) 

      -


      -


      (75)


      -


      Non-GAAP income before income taxes

      $ 2,946


      $     2,919


      $ 5,802


      $     5,783











      GAAP provision for income taxes

      $    351


      $        391


      $    659


      $        780


      Adjustments to provision for income taxes:









      Income tax effect of the above adjustments (e) 

      74


      117


      138


      236


      Other income tax adjustments (f)

      (8)


      1


      10


      24


      Total adjustments to provision for income taxes

      66


      118


      148


      260


      Non-GAAP provision for income taxes

      $    417


      $        509


      $    807


      $     1,040











      GAAP tax as a percentage of income before taxes

      13.3%


      15.4%


      12.5%


      15.6%


      Adjustments to provision for income taxes:









      Income tax effect of the above adjustments (e) 

      1.2


      2.0


      1.2


      2.0


      Other income tax adjustments (f)

      -0.3


      0.0


      0.2


      0.4


      Total adjustments to provision for income taxes

      0.9


      2.0


      1.4


      2.4


      Non-GAAP tax as a percentage of income before taxes

      14.2%


      17.4%


      13.9%


      18.0%











      GAAP net income

      $ 2,296


      $     2,151


      $ 4,607


      $     4,222


      Adjustments to net income:









      Adjustments to income before income taxes, net of the income tax effect

      225


      260


      398


      545


      Other income tax adjustments (f)

      8


      (1)


      (10)


      (24)


      Total adjustments to net income

      233


      259


      388


      521


      Non-GAAP net income

      $ 2,529


      $     2,410


      $ 4,995


      $     4,743

      Amgen Inc.

      GAAP to Non-GAAP Reconciliations

      (In millions, except per share data)

      (Unaudited)




















      The following table presents the computations for GAAP and non-GAAP diluted EPS



















      Three months ended


      Three months ended



      June 30, 2018


      June 30, 2017



      GAAP


      Non-GAAP


      GAAP


      Non-GAAP











      Net income

      $ 2,296


      $     2,529


      $ 2,151


      $     2,410


      Weighted-average shares for diluted EPS

      660


      660


      738


      738


      Diluted EPS

      $   3.48


      $       3.83


      $   2.91


      $       3.27












      Six months ended


      Six months ended



      June 30, 2018


      June 30, 2017



      GAAP


      Non-GAAP


      GAAP


      Non-GAAP











      Net income

      $ 4,607


      $     4,995


      $ 4,222


      $     4,743


      Weighted-average shares for diluted EPS

      685


      685


      740


      740


      Diluted EPS

      $   6.73


      $       7.29


      $   5.71


      $       6.41










      (a)

      The adjustments related primarily to non-cash amortization of intangible assets acquired in business combinations.










      (b)

      For the six months ended June 30, 2017, the adjustment related primarily to severance expenses associated with our restructuring initiative.










      (c)

      For the three and six months ended June 30, 2018, the adjustment related primarily to the change in fair values of contingent consideration liabilities.










      (d)

      For the six months ended June 30, 2018, the adjustment related to the net gain associated with the Kirin-Amgen share acquisition.










      (e)

      The tax effect of the adjustments between our GAAP and non-GAAP results takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). Generally, this results in a tax impact at the U.S. marginal tax rate for certain adjustments, including the majority of amortization of intangible assets, whereas the tax impact of other adjustments, including restructuring expense, depends on whether the amounts are deductible in the respective tax jurisdictions and the applicable tax rate(s) in those jurisdictions. Due to these factors, the effective tax rates for the adjustments to our GAAP income before income taxes, for the three and six months ended June 30, 2018 were 24.7% and 25.7%, compared with 31.0% and 30.2% for the corresponding periods of the prior year.










      (f)

      The adjustments related primarily to certain acquisition items and prior period items excluded from GAAP earnings. 



      Amgen Inc.

      Reconciliations of Cash Flows

      (In millions)

      (Unaudited)




      Three months ended


      Six months ended



      June 30,


      June 30,



      2018


      2017


      2018


      2017


      Net cash provided by operating activities

      $   2,102


      $ 2,326


      $   4,829


      $ 4,711


      Net cash provided by (used in) investing activities

      2,938


      (1,813)


      17,844


      (1,970)


      Net cash used in financing activities

      (4,650)


      (1,242)


      (16,342)


      (3,353)


      Increase (decrease) in cash and cash equivalents

      390


      (729)


      6,331


      (612)


      Cash and cash equivalents at beginning of period

      9,741


      3,358


      3,800


      3,241


      Cash and cash equivalents at end of period

      $  10,131


      $ 2,629


      $  10,131


      $ 2,629





















      Three months ended


      Six months ended



      June 30,


      June 30,



      2018


      2017


      2018


      2017


      Net cash provided by operating activities

      $   2,102


      $ 2,326


      $   4,829


      $ 4,711


      Capital expenditures

      (187)


      (185)


      (342)


      (353)


      Free cash flow

      $   1,915


      $ 2,141


      $   4,487


      $ 4,358


      Reconciliation of GAAP EPS Guidance to Non-GAAP

      EPS Guidance for the Year Ending December 31, 2018

      (Unaudited)















      GAAP diluted EPS guidance



      $ 11.83

      -

      $ 12.62








      Known adjustments to arrive at non-GAAP*:







       

      Acquisition-related expenses (a)



      1.35



       

      Restructuring charges


      0.02

      -

      0.11


       

      Certain other expenses



      0.03



       

      Tax adjustments (b)



      (0.02)


      Non-GAAP diluted EPS guidance



      $ 13.30

      -

      $ 14.00




      *


      The known adjustments are presented net of their related tax impact, which amount to approximately $0.40 per share, in the aggregate.




      (a)


      The adjustments relate primarily to non-cash amortization of intangible assets acquired in business combinations.




      (b)


      The adjustments relate primarily to certain acquisition items and prior period items excluded from GAAP earnings.






      Our GAAP diluted EPS guidance does not include the effect of GAAP adjustments triggered by events that may occur subsequent to this press release such as acquisitions, asset impairments, litigation and changes in the fair value of our contingent consideration.



      Reconciliation of GAAP Tax Rate Guidance to Non-GAAP


      Tax Rate Guidance for the Year Ending December 31, 2018


      (Unaudited)
















      2018








      GAAP tax rate guidance


      12.5%

      -

      13.5%









      Tax rate effect of known adjustments discussed above



      1.0%









      Non-GAAP tax rate guidance


      13.5%

      -

      14.5%

      SOURCE Amgen

      Modal title

      Also from this source

      AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE

      AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE

      Amgen (NASDAQ: AMGN) today announced results from the Phase 3 OASIZ-301 study of dazodalibep, the only global Phase 3 trial to demonstrate clinically ...

      NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM

      NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM

      Amgen (NASDAQ: AMGN) today announced new data at the American Heart Association (AHA) Scientific Sessions 2026 that further strengthen the case for...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.